866-997-4948(US-Canada Toll Free)

Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Metabolic Disorders

No. of Pages : 72 Pages


This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing\'s Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing\'s Disease) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing\'s Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Pituitary ACTH Hypersecretion (Cushing\'s Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Pituitary ACTH Hypersecretion (Cushing\'s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pituitary ACTH Hypersecretion (Cushing\'s Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing\'s Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing\'s Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pituitary ACTH Hypersecretion (Cushing\'s Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Overview 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Comparative Analysis 10
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Therapeutics under Development by Companies 11
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Therapeutics under Investigation by Universities/Institutes 13
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Products under Development by Companies 17
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Products under Investigation by Universities/Institutes 18
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Companies Involved in Therapeutics Development 19
Isis Pharmaceuticals, Inc. 19
Ipsen S.A. 20
Novartis AG 21
Corcept Therapeutics Incorporated 22
HRA Pharma, SA 23
Cortendo Invest AB 24
Orphagen Pharmaceuticals, Inc. 25
ElexoPharm GmbH 26
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 39
mifepristone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
mifepristone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mifepristone - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ketoconazole - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pasireotide LAR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LCI-699 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DG-3173 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ISIS-GCCRRx - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Next Generation Cortisol Inhibitor - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule to Inhibit CYP11B1 for Cushing Disease - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peptides to Antagonize ACTH Receptor for Cushing Syndrome - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Steroidogenic Factor-1 Antagonists - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drug to Inhibit Melanocortin Receptor 2 for Cushing Disease - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Recent Pipeline Updates 57
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Dormant Projects 63
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Product Development Milestones 64
Featured News & Press Releases 64
Dec 15, 2012: Novartis\'s Signifor Gains FDA Approval As First Medication To Treat Cushing\'s disease 64
Nov 07, 2012: FDA Advisory Committee Recommends Novartis\'s Signifor For Approval To Treat Patients With Cushing\'s Disease 65
Nov 05, 2012: Novartis\'s Drug Pasireotide Effective Against Cushings Disease, FDA Reviewers Find 65
Jul 30, 2012: Cortendo\'s NormoCort Receives Orphan Drug Designation From EMA To Treat Cushings Syndrome 66
Apr 25, 2012: Novartis\'s Signifor Receives Approval In EU For Patients With Cushing\'s Disease 66
Apr 10, 2012: Corcept Therapeutics Launches Korlym For Patients With Endogenous Cushings Syndrome 67
Apr 09, 2012: Corcept Announces Publication Of Phase III Trial Results Of Korlym In Journal of Clinical Endocrinology and Metabolism 68
Mar 26, 2012: Corcept Selects PharmaForm As Primary Commercial Manufacturer For Korlym 69
Mar 22, 2012: Corcept Therapeutics To Ship Korlym For Patients With Endogenous Cushing\'s Syndrome By April 11, 2012 69
Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushings Syndrome 70

Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Table


Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing\'s Disease), H1 2014 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 19
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by Ipsen S.A., H1 2014 20
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by Novartis AG, H1 2014 21
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by Corcept Therapeutics Incorporated, H1 2014 22
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by HRA Pharma, SA, H1 2014 23
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by Cortendo Invest AB, H1 2014 24
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 25
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Pipeline by ElexoPharm GmbH, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 38
Pituitary ACTH Hypersecretion (Cushing\'s Disease) Therapeutics - Recent Pipeline Updates, H1 2014 57
Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Dormant Projects, H1 2014 63

List of Chart


Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing\'s Disease), H1 2014 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing\'s Disease) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *